PD-1 Inhibitors Maintenance for cHL Post-autoHCT
NCT06812858
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
83
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
Nivolumab, Pembrolizumab
Sponsor
St. Petersburg State Pavlov Medical University